BUB1 Inhibition Sensitizes TNBC Cell Lines to Chemotherapy and Radiotherapy
Preprint
- 24 April 2024
- preprint
- Published by MDPI AG in Preprints.org
Abstract
BUB1 is overexpressed in most human solid cancers including breast cancer. Higher BUB1 levels are associated with poor prognosis especially in patients with triple-negative breast cancer (TNBC). Women with TNBC often develop resistance to chemotherapy and radiotherapy, which are still the mainstay of treatment for TNBC. Our previous studies demonstrated that BUB1 kinase inhibitor (BAY1816032) reduced tumor cell proliferation and significantly enhanced radiotherapy efficacy in TNBC. In this study, we evaluated the effectiveness of BAY1816032 with a PARP inhibitor (olaparib), platinum agent (cisplatin), and microtubule poison (paclitaxel) alone or in combination with radiotherapy using cytotoxicity and clonogenic survival assays. BUB1 inhibitor sensitized BRCA1/2 wild-type SUM159 and MDA-MB-231 cells to olaparib, cisplatin and paclitaxel synergistically (combination index; CIKeywords
All Related Versions
- Version 1, 2024-04-24, Preprints
- Published version: Biomolecules, 14 (6), 625.
This publication has 65 references indexed in Scilit:
- Inhibition of RRM2 radiosensitizes glioblastoma and uncovers synthetic lethality in combination with targeting CHK1Cancer Letters, 2023
- Molecular targets that sensitize cancer to radiation killing: From the bench to the bedsideBiomedicine & Pharmacotherapy, 2022
- A Phase 1 Dose-Escalation Trial of Radiation Therapy and Concurrent Cisplatin for Stage II and III Triple-Negative Breast CancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2021
- DNA damage response inhibitors: An avenue for TNBC treatmentBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2021
- Olaparib monotherapy as primary treatment in unselected triple negative breast cancerAnnals of Oncology, 2021
- Non-small cell lung cancer cells with deficiencies in homologous recombination genes are sensitive to PARP inhibitorsBiochemical and Biophysical Research Communications, 2020
- Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cellsBiomedicine & Pharmacotherapy, 2018
- Cisplatin in cancer therapy: Molecular mechanisms of actionEuropean Journal of Pharmacology, 2014
- Targeted radiosensitization with PARP1 inhibition: optimization of therapy and identification of biomarkers of response in breast cancerBreast Cancer Research and Treatment, 2014
- Analysis of pattern, time and risk factors influencing recurrence in triple-negative breast cancer patientsMedical Oncology, 2013